Vangene Non-Invasive Prenatal Test (NIPT)
- Home
- Vangene Non-Invasive Prenatal Test (NIPT)
Vangene Non-Invasive Prenatal Test (NIPT)
What is Vangene Non-Invasive Prenatal Test (NIPT) ?
The Vangene Non-Invasive Prenatal Test (NIPT) serves as a screening method for assessing the risk of diseases arising from chromosomal abnormalities in the fetus through analysis of the mother’s blood. Employing cutting-edge technology and examination tools sourced from the United States, this test yields highly accurate results, surpassing 99%, and encompasses major chromosomal abnormalities as well as symptoms associated with Microdeletion or Microduplication, covering up to 100 symptoms. All of this is provided at an affordable price point.
Clinical validation data
| Trisomy 21 | Trisomy 18 | Trisomy 13 | |
| Sensitivity | >99% | >99% | >99% |
| Specificity | >99% | >99% | >99% |
JeonYJ, ZhouY, Li Y,GuoQ, ChenJ, et al. (2014) TheFeasibilityStudyofNon-InvasiveFetal Trisomy18and21DetectionwithSemiconductor SequencingPlatform.PLoSONE9(10):e110240.doi:10.1371/journal.pone.0110240
Liao, C., Yin, A. H., Peng, C. F., Fu, F., Yang, J. X., Li, R., … & Zhang, K. (2014). Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing. Proceedings of the National Academy of Sciences, 111(20), 7415-7420.
Kim, S., Jung, H., Han, S. H., Lee, S., Kwon, J., Kim, M. G., … & Bhak, J. (2016). Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy. BMC medical genomics, 9(1), 1-7.
Liao, C., Yin, A. H., Peng, C. F., Fu, F., Yang, J. X., Li, R., … & Zhang, K. (2014). Noninvasive prenatal diagnosis of common aneuploidies by semiconductor sequencing. Proceedings of the National Academy of Sciences, 111(20), 7415-7420.
Kim, S., Jung, H., Han, S. H., Lee, S., Kwon, J., Kim, M. G., … & Bhak, J. (2016). Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy. BMC medical genomics, 9(1), 1-7.
Who should get tested?
- All expectant mothers starting from the 12th week of pregnancy onward.
- Pregnant individuals aged 35 and above.
- Pregnant women under 35 who have not undergone any previous screening.
- Pregnant individuals identified as at higher risk for abnormalities through serum screening tests.
- Certain abnormalities detected through ultrasound examinations.
- Couples with a history of children with chromosomal abnormalities.
- Couples with a history of infertility.
Key highlight
- Conducted as a one-time screening for abnormalities on chromosomes 21, 18, 13, and sex chromosomes, including symptoms of Microdeletion or Microduplication, covering a maximum of 93 symptoms.
- Available for screening from the 12th week of pregnancy onward.
- Achieves high accuracy exceeding 99% with a minimal false positive or false negative rate.
- Requires only a 10 milliliter blood sample, posing no risk to the fetus.
- Delivers results promptly within 10-14 days.
- Accompanied by certified academic testing information.
- Financial support limitations are considered in cases where test results indicate high risk.
- Professional insurance coverage is provided in case of errors.
- Expert advice is available from doctors and specialists throughout the process.
Conditions Screened For
- Chromosomal irregularities encompassing chromosomes 21 (Down syndrome), 18 (Edwards syndrome), and 13 (Patau syndrome).
- Sex chromosome abnormalities, including Turner Syndrome (Monosomy X/XO), Klinefelter Syndrome (XXY), and Triple X Syndrome (XXX).
- Microdeletion syndromes comprise DeGeorge syndrome, 1p36 syndrome, Angelman syndrome, Prader-Willi syndrome, and associated symptoms of Microdeletion or Microduplication, totaling 93 symptoms.
Sample Collection
- Collect a 10-milliliter blood sample from the pregnant mother starting at 12 weeks of pregnancy. Place the sample in a Vangene cfDNA tube for further processing.
Package
| Trisomy 21 (Down Syndrome) | ||
| Trisomy 18 (Edwards’ Syndrome) | ||
| Trisomy 13 (Patau syndrome) | ||
Sex chromosome aneuploidies:
|
||
| Fetal sex report | ||
| Other chromosomal anomalies | ||
6 Microdeletion:
|
||
87 อาการในกลุ่ม Microdeletion หรือ Microduplication syndromes ที่มีขนาดการขาดหายหรือเพิ่มเติมของชิ้นโครโมโซมมากกว่า 10Mb เช่น
|
||
| Turn-around-time | 10-14 days after receiving the blood sample | 10-14 days after receiving the blood sample |
